Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$233.50 USD
-1.13 (-0.48%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $233.47 -0.03 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Price, Consensus and EPS Surprise
BDX 233.50 -1.13(-0.48%)
Will BDX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BDX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BDX
4 Stocks to Buy Amid Dental Supplies Industry Challenges
BD Stock Rises as Neopak XtraFlow Syringe Expands in Biologics
BDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Medtronic Keeps Capturing High-Growth Markets: Time to Buy MDT Stock?
Here's Why Becton Dickinson (BDX) is a Strong Value Stock
Here's Why Becton Dickinson (BDX) is a Strong Value Stock
Other News for BDX
Embecta Corp.: Navigating Through A Changing Landscape
BD Expands Capacity for Advanced Prefillable Syringes and Enhances Injection Experience for the Next Generation of Biologics
Becton Dickinson announces commercial release of BD Neopak XtraFlow
BCAL Diagnostics Issues Shares, Complies with Regulations
BCAL Diagnostics Director Increases Shareholding